By Twesha Dikshit and Ragini Mathur (Reuters) -European shares closed flat on Wednesday, surrendering early session gains, as ...

There is no certainty that the buyout will come to pass, according to The Financial Times, which first reported the rumors.

If a deal is confirmed and consummated, Novartis would claim ownership of a biotech that has raised something of a stir in ...

Cancer vaccine experts are worried that if the Trump administration takes a hostile posture towards mRNA broadly, cancer ...

Today, the regulator revealed FDA PreCheck, which introduces a two-phase approach to getting approval for new production ...

--Novartis made a takeover approach for Avidity Biosciences, a biotechnology company that specializes in rare diseases with a market value of $5.8 billion, the Financial Times reports, citing unnamed ...

The US Food and Drug Administration (FDA) has approved a label expansion to Teva’s Ajovy in certain children and adolescents, ...

Genmab (NASDAQ: GMAB) also cited higher sales of its own cancer drug EPKINLY as a key driver of its performance. Meanwhile, net sales of DARZALEX rose 22% to $6.78 billion over the period.

A new American Heart Association initiative is working to increase screening for lipoprotein(a) (Lp[a]) at community health ...

Yet, within the past 24 hours, Trump has doubled the tariffs on India to 50%, imposed an additional 15% on Japan, announced a ...

Avidity Biosciences stock rocketed Wednesday on a report Novartis made an attempt to buy the rare disease-focused biotech ...

Meanwhile, mRNA vaccine maker Moderna is cutting around 500 jobs (10% of its workforce) as part of a commitment to save $1.5 ...